• PF-04971729 (Ertugliflozin): Applied SGLT2 Inhibition in Res

  2026-05-09

  Ertugliflozin (PF-04971729) streamlines renal glucose transport studies with high selectivity, enabling robust diabetes mellitus research and cardiovascular risk modeling. This guide details optimized protocols, troubleshooting strategies, and practical assay integration, drawing on recent meta-analytic evidence and real-world workflow insights.

• LC-MS/MS Metabolomics Reveals Resistance in Carbapenemase-Pr

  2026-05-09

  This study applies LC-MS/MS metabolomics to distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE strains, identifying 21 predictive metabolite biomarkers and key altered pathways. The findings provide a rapid, biomarker-driven approach for characterizing resistance phenotypes and inform the development of targeted diagnostics in antibiotic resistance research.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-05-08

  Canagliflozin stands out in metabolic and renal disease research by combining potent SGLT2 inhibition with direct mitochondrial modulation in proximal tubular cells. This article delivers actionable protocols, troubleshooting insights, and evidence-based guidance for maximizing translational impact in both in vitro and in vivo models.

• Heptamethine Cyanine Dye Suppresses PR in HR+ Breast Cancer

  2026-05-07

  This study introduces CA800-PR, a tumor-targeted, water-soluble heptamethine cyanine dye that selectively suppresses progesterone receptor (PR) activity in hormone receptor-positive (HR+) breast cancer models. The findings reveal that CA800-PR induces Golgi fragmentation and immunogenic cell death, offering a new therapeutic mechanism distinct from traditional hormone therapies and with implications for live-cell organelle imaging approaches.

• Canagliflozin: SGLT2 Inhibitor Workflows for Renal Research

  2026-05-07

  Canagliflozin stands apart as a potent SGLT2 inhibitor, not only lowering glucose reabsorption but also remodeling mitochondrial structure in diabetic kidneys. This article delivers actionable protocol guidance and troubleshooting insights for leveraging Canagliflozin in advanced metabolic and renal research.

• HOBt (1-Hydroxybenzotriazole): Optimizing Amide Bond Formati

  2026-05-06

  HOBt (1-Hydroxybenzotriazole) stands at the forefront of peptide and complex amide synthesis, minimizing epimerization and elevating reproducibility. Discover how APExBIO’s high-purity HOBt streamlines workflows, solves common troubleshooting pitfalls, and empowers advanced applications from peptide drugs to antibiotic derivatives.

• Technical Use of HyperScribe™ T7 High Yield Cy3 RNA Labeling

  2026-05-06

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus enables efficient, high-yield synthesis of randomly Cy3-labeled RNA probes for applications such as in situ hybridization and Northern blot analysis. This kit should be used exclusively in research workflows focused on RNA localization or expression, and is not suitable for diagnostic or therapeutic purposes.

• VEGFC–VEGFR-3 Axis in NASH Fibrosis: Insights from Naringin

  2026-05-05

  This study elucidates how the VEGFC–VEGFR-3 signaling axis drives hepatic fibrosis in NASH and demonstrates that both naringin and the VEGFR-3 inhibitor SAR131675 disrupt this axis to ameliorate disease. The findings position VEGFC as a critical molecular target in the hepatocyte-macrophage regulatory circuit underlying NASH-associated liver fibrosis.

• Mitomycin C: Elevating Antitumor Antibiotic Workflows in Can

  2026-05-05

  Mitomycin C stands out as a precision antitumor antibiotic, uniquely enabling robust, reproducible apoptosis and DNA replication inhibition studies. This article demystifies advanced applications, protocol fine-tuning, and troubleshooting strategies for deploying Mitomycin C from APExBIO in cutting-edge cancer research.

• EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Mechanism & Bench

  2026-05-04

  EZ Cap™ Firefly Luciferase mRNA (5-moUTP) is a chemically modified, in vitro transcribed mRNA designed for robust bioluminescent reporter gene expression. The incorporation of 5-methoxyuridine and a Cap 1 structure enables high translation efficiency and reduced innate immune activation, making it a powerful tool for mRNA delivery and translation efficiency assays in mammalian cells.

• LDN-193189 in Stem Cell Plasticity: BMP Inhibition Redefined

  2026-05-04

  Explore how LDN-193189, a potent ALK inhibitor, advances research on BMP signaling and stem cell plasticity. This article uniquely bridges molecular mechanisms with assay optimization, offering actionable insights beyond standard protocol guides.

• Sulfamonomethoxine: Optimized Protocols for Veterinary & Aqu

  2026-05-03

  Sulfamonomethoxine (SMM) stands out as a versatile veterinary and aquaculture antibiotic, enabling both robust infection control and cutting-edge environmental toxicity workflows. This guide demystifies advanced experimental setups, troubleshooting tactics, and the integration of SMM in high-impact research, drawing from the latest reference breakthroughs and best practices.

• Cy3 TSA Fluorescence System Kit: Enabling Single-Cell Epigen

  2026-05-02

  Explore how the Cy3 TSA Fluorescence System Kit empowers single-cell and spatial epigenetics, leveraging tyramide signal amplification for ultrasensitive detection. Discover unique insights and practical guidance for advanced fluorescence microscopy workflows.

• Weight Loss Restores Intestinal Stretch Regulation of Satiet

  2026-05-02

  This study reveals that acute intestinal stretch suppresses food intake and improves glucose tolerance independently of classical gut hormones, but these effects are impaired in obesity and restored after weight loss. The findings highlight an underappreciated mechanism in metabolic regulation, with implications for understanding interventions like dietary changes and bariatric surgery.

• Fe3O4@ZIF-8 Nanoparticles for Dual Antibiosis and Osteogenes

  2026-05-01

  This study introduces Fe3O4@ZIF-8 core–shell nanoparticles that simultaneously exert pH-triggered antibacterial action and promote bone regeneration, addressing persistent infection and defect repair in jaw osteomyelitis. The research offers a new strategy for overcoming antibiotic resistance and inadequate bone healing in clinical settings.

16114 records 1/1075 page Next 12345 下5页 Last page